Agresja profesorów, Sanepidu i sędziny – a testy na dzieciach?

Źródło

Prof. Dorota Majewska

Warto się zastanowić czy istnieje związek między przejawami niespotykanej agresji (niemal cielesnej) wobec nieszczepiących rodziców ze strony profesorów, Sanepidu i sędziny z sadu administracyjnego z Poznania, a faktem, że Uniwersytet Medyczny w tym mieście jest głównym ośrodkiem w Polsce, w którym testuje się na tysiącach dzieci nowe szczepionki koncernów farmaceutycznych. Jest to zapewne intratne źródło dochodów dla wielu osób w tym regionie, które lobbują za masowymi szczepieniami.

Może w wyjątkowej agresji tych osób (którą obserwujemy w mediach) chodzi o szeroki dostęp do niemowląt-królików doświadczalnych? Ciekawe, czy rodzice dzieci, które brały udział w tych testach wiedzieli, że ich dzieci są królikami? Ile było poważnych NOP-ów wśród tych dzieci? To publikacje, jak zwykle, przemilczają . Wiadomo, że w Polsce wcale nierzadko się spotyka sytuacje, kiedy pacjenci są nieświadomi, że prowadzi się na nich doświadczenia. W sytuacji, kiedy – jak groziła sędzina administracyjna z Poznania – polskie dzieci będzie się szczepić na siłę, wbrew woli rodziców, nietrudno sobie wyobrazić przymusowe eksperymenty na dzieciach, przypominające doświadczenia dra Mengele z Auschwitz.

Poniżej kilka publikacji dotyczących testowania szczepionek na niemowlętach z poznańskiego ośrodka.

Pozdrawiam

DM

——–

Vaccine. 2010 Nov 16;28(49):7779-86. Epub 2010 Sep 28.

Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines.

Wysocki J, Tansey S, Brachet E, Baker S, Gruber W, Giardina P, Arora A.

Source

Poznan University of Medical Sciences, Poznan, Poland.

Abstract

A randomised, open-label study compared the immunogenicity and safety of 7-valent pneumococcal conjugate vaccine (PCV7) and meningococcal C conjugate vaccine (MnCC vaccine) administered concomitantly and individually. Infants received PCV7+MnCC vaccine (n=265), PCV7 alone (n=268) or MnCC vaccine alone (n=178). PCV7 was administered at 2, 3½, 6 and 12 months, and MnCC vaccine at 2, 6 and 12 months. For the 7 pneumococcal serotypes tested (4, 6B, 9V, 14, 18C, 19F and 23F), proportions of subjects with pneumococcal serotype-specific immunoglobulin G (IgG) antibody concentrations ≥0.35 μg/mL post-infant series were non-inferior for the PCV7+MnCC vaccine (91.5-99.6%) and PCV7 (89.0-99.6%) groups. Proportions of subjects achieving serogroup C meningococcal serum bactericidal assay titres ≥1:8 post-infant series were non-inferior for the PCV7+MnCC vaccine (99.6%) and MnCC vaccine groups (98.8%). Pneumococcal IgG antibody levels were similar in the PCV7+MnCC vaccine and PCV7 groups at each time point. Post-infant and post-toddler meningococcus C serum bactericidal assay titres and IgG levels were similar in the PCV7+MnCC vaccine and MnCC groups, although pre-toddler, the levels were lower in the PCV7+MnCC vaccine group than the MnCC vaccine group. Immune response rates to diphtheria antigen approached 100% for all vaccine groups. Local reactions were mostly similar among the treatment groups. The MnCC vaccine group had lower rates of some systemic events than the PCV7+MnCC vaccine group. Immune responses to PCV7+MnCC vaccine were non-inferior compared with those seen with each vaccine administered alone.

Copyright © 2010 Elsevier Ltd. All rights reserved.

PMID: 20883736

[PubMed - indexed for MEDLINE]

2. Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S77-88.

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.

Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L.

Source

University School of Medical Sciences & Regional Medical Center for Mother and Child, Poznan, Poland.

Abstract

BACKGROUND:

Immunogenicity of the candidate 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was assessed when coadministered with other routine pediatric vaccines including different Neisseria meningitidis serogroup C conjugate vaccines.

METHODS:

One thousand five hundred forty-eight healthy infants received, according to a balanced (1:1:1:1) randomization, either PHiD-CV coadministered with (1) DTPa-HBV-IPV/Hib (Infanrix hexa) and MenC-CRM (Meningitec), (2) DTPa-HBV-IPV/Hib and MenC-TT (NeisVac-C), or (3) DTPa-HBV-IPV (Infanrix penta/Pediarix) and Hib-MenC-TT (Menitorix); or 7vCRM (Prevenar/Prevnar) coadministered with DTPa-HBV-IPV and Hib-MenC-TT at 2-4-6 months of age with a booster dose at 11-18 months. Serotype-specific pneumococcal responses were measured by 22F-inhibition ELISA and opsonophagocytic (OPA) assay.

RESULTS:

In all 3 coadministration groups, PHiD-CV was immunogenic for each of the 10 pneumococcal vaccine serotypes as assessed by post-primary and post-booster antibody ELISA and OPA responses. When coadministered with DTPa-HBV-IPV, Hib, and MenC antigens, PHiD-CV responses after the third primary dose were within the same range as 7vCRM responses in terms of the percentage of subjects achieving an ELISA antibody concentration >or=0.2 microg/mL for all common vaccine serotypes (over 92% of subjects) except for serotype 6B (at least 87% of subjects). ELISA and OPA immune responses were also evident after the second primary doses of PHiD-CV or 7vCRM vaccine, although antibody levels were below that achieved after 3 primary doses, particularly for serotypes 6B and 23F. The kinetics of the immune responses from after the second dose to after the booster dose were similar for most of the serotypes in both PHiD-CV and 7vCRM groups.

CONCLUSIONS:

PHiD-CV was immunogenic when coadministered with other routine pediatric vaccines including MenC conjugate vaccines.

PMID:

3. Vaccine. 2008 Sep 26;26(41):5296-303. Epub 2008 Aug 27.

Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age.

Pietrzyk JJ, Wysocki J, Pejcz J, Galaj A, Majda-Stanislawska E, Käyhty H, Thierry-Carstensen B, Jensen AM.

Source

Jagellonian University, Medical College, Institute of Pediatrics, Department of Pediatrics, Wielicka 265, 30-663 Krakow, Poland.

Abstract

In a phase III, double blind, randomized, noninferiority, multi-centre clinical trial, 817 infants were included and randomly assigned to vaccination with DTaP-IPV(Vero) (N=410) or DTaP-IPV(Mkc) (N=407) vaccines (Statens Serum Institut (SSI), Denmark) in the right thigh. All infants were vaccinated with Act-HIB (Sanofi Pasteur, France) in the left thigh at the same time. The vaccination schedule was 2, 3.5, 5 and 16 months and serum samples were obtained at 6, 16 and 17 months. The primary objective was to demonstrate noninferiority of DTaP-IPV(Vero) to DTaP-IPV(Mkc) as regards immunological protection against polio virus types 1, 2 and 3. Furthermore, the immunogenicity of all vaccine antigens and the safety profile of the vaccines were assessed. The study demonstrated that DTaP-IPV(Vero) was noninferior to DTaP-IPV(Mkc). All antibody concentrations/titres remained at an acceptable level from the end of the primary vaccination series (i.e. 2, 3.5 and 5 months) until the time of the booster vaccination at 16 months. A good booster response was, furthermore, demonstrated for all antigens. No vaccine-related serious adverse events and no injection site granulomas or swelling of the entire thigh occurred. The frequencies of local injection site erythema and swelling as well as systemic adverse events such as fever, irritability, somnolence and decreased appetite were low and acceptable in both treatment groups. In conclusion, DTaP-IPV(Vero) is immunogenic and safe for primary vaccination and for booster vaccination of healthy children.

PMID: 18675870

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Arora%20A%22%5BAuthor%5D